Please ensure Javascript is enabled for purposes of website accessibility

Why Tonix Pharmaceuticals Is Up by 6% Today

By Eric Volkman – Nov 23, 2021 at 2:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's path to regulatory approval for a key pipeline drug just got a bit shorter.

What happened

Tonix Pharmaceuticals (TNXP -2.50%), a rather up-and-down meme stock in the biotech sector, was having a fine day on the market Tuesday. And this wasn't because of some online hype from a meme stock investor; instead the company reported some encouraging news about a key pipeline drug.

So what

Tuesday morning, Tonix was all too happy to announce that the Food and Drug Administration (FDA) has cleared the Investigational New Drug application for its TNX-1900. That nod paves the way for Tonix to begin a phase 2 study of the drug for the prevention of migraines in chronic patients.

A medical professional using a microscope.

Image source: Getty Images.

The treatment of migraines has been a thorny challenge for biotechs and pharmaceutical companies for many years. According to Tonix, roughly 4 million people in the U.S. suffer from chronic migraines, presenting a robust patient base for the company should TNX-1900 eventually be authorized or approved by the regulator.

In the press release trumpeting the FDA's move, Tonix quoted its CEO Seth Lederman as saying of its pipeline drug, "We believe that by engaging and stimulating oxytocin receptors in the trigeminal ganglia, TNX-1900 has the potential to help chronic migraine sufferers."

Oxytocin, a hormone, is perhaps best known for its role in controlling and regulating important aspects of the human reproductive system.

Now what

Tonix said that it anticipates beginning enrollment in the phase 2 study in the second half of next year. The company has ambitions beyond migraine treatment for the drug; it added that it also plans to develop it for craniofacial pain and insulin resistance.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.